68Ga-Pentixafor PET/CT Improves the Detection of Recurrent Myeloma in the Temporal Bone Masked by the Physiological 18F-FDG Uptake of the Brain and Extraocular Muscles. (10th April 2022)

• Record Type: Journal Article
• Authors: Pan, Qingqing; Luo, Yaping; Cao, Xinxin; Li, Jian
• Is Part Of: Clinical nuclear medicine. Volume 47:Number 4(2022)
• Page Start: e348
• Page End: e350
• Publication Date: 2022-04-10
• Subjects: multiple myeloma -- 68Ga-pentixafor -- PET/CT; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000003979
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: A 71-year-old woman was recently diagnosed with multiple myeloma. Baseline 18 F-FDG and 68 Ga-pentixafor PET/CT showed diffusely increased uptake in bone marrow, consistent with infiltrated myeloma. She had very good partial response after 9 cycles of chemotherapy. However, during the maintenance with ixazomib, she experienced progressed disease. In the follow-up PET/CT, except for diffusely infiltrated disease in bone marrow, 68 Ga-pentixafor PET/CT additionally detected a new emerging lesion in the right temporal bone with lytic bone destruction, which was initially missed in 18 F-FDG PET/CT due to the intense physiological uptake of the brain and extraocular muscles.